Astellas Cresemba Clears FDA For Orphan, But Not Limited, Populations
Executive Summary
Firm adds third antifungal to its portfolio.
You may also be interested in...
Sanofi’s Praluent Closes Gap On Repatha In Europe, As GSK Gets Green Light For World’s First Malaria Vaccine
Europe’s CHMP grants positive opinions for Sanofi’s Praluent and GSK’s not-for-profit malaria vaccine Mosquirix at July meeting; other products recommended include Shire’s Intuniv, Merck’s Zerbaxa, Basilea’s Cresemba and Keryx’s Fexeric.
Astellas Antifungal Nabs 12-Year Exclusivity: QIDP+Orphan Combos Are Rare
Cresemba (isavuconazonium), the first antifungal approved with added exclusivity award for Qualified Infectious Disease Products, also becomes first product to receive both QIDP and Orphan Drug exclusivity.
Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up
Deal brings CHF75 million upfront plus welcome validation after Basilea's break-up with J&J on ceftobiprole.